ASO Author Reflections: Novel Evidence on Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer with Arterial Involvement

被引：0
|
作者：
Ikenaga, Naoki [1 ]
Miyasaka, Yoshihiro [2 ]
Ohtsuka, Takao [3 ]
Nakamura, Masafumi [1 ]
机构：
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka, Japan
[2] Fukuoka Univ, Chikushi Hosp, Dept Surg, Chikushino, Japan
[3] Kagoshima Univ, Grad Sch Med Sci, Digest Surg Breast & Thyroid Surg, Kagoshima, Japan
来源：
ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / 01期
关键词：
D O I：
10.1245/s10434-022-12584-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：203 / 204
页数：2
相关论文
共 50 条
  • [21] Pathological Response and Adjuvant Chemotherapy are Prognostic Factors for Relapse Free Survival After Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer With Arterial Involvement
    Saito, K.
    Nakai, Y.
    Arita, J.
    Kazunaga, I.
    Takahara, N.
    Hasegawa, K.
    Koike, K.
    PANCREAS, 2019, 48 (10) : 1513 - 1514
  • [22] ASO Author Reflections: Future Prospects of Neoadjuvant Chemotherapy for Gastric Cancer
    Masayuki Kano
    Hisahiro Matsubara
    Annals of Surgical Oncology, 2020, 27 : 721 - 722
  • [23] ASO Author Reflections: Future Prospects of Neoadjuvant Chemotherapy for Gastric Cancer
    Kano, Masayuki
    Matsubara, Hisahiro
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (Suppl 3) : 721 - 722
  • [24] Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
    Roberto Alva-Ruiz
    Lavanya Yohanathan
    Jennifer A. Yonkus
    Amro M. Abdelrahman
    Lindsey A. Gregory
    Thorvadur R. Halfdanarson
    Amit Mahipal
    Robert R. McWilliams
    Wen Wee Ma
    Christopher L. Hallemeier
    Rondell P. Graham
    Travis E. Grotz
    Rory L. Smoot
    Sean P. Cleary
    David M. Nagorney
    Michael L. Kendrick
    Mark J. Truty
    Annals of Surgical Oncology, 2022, 29 : 1579 - 1591
  • [25] Neoadjuvant Chemoradiotherapy for Resectable and Borderline Resectable Pancreatic Cancer
    Attaallah, Wafi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 3346 - +
  • [26] Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer
    Kumar, Rachit
    Jabbour, Salma K.
    JOURNAL OF RADIATION ONCOLOGY, 2013, 2 (04) : 353 - 367
  • [27] Neoadjuvant Chemoradiotherapy for Resectable and Borderline Resectable Pancreatic Cancer
    Hayakawa, S.
    Karasawa, K.
    Fujisawa, T.
    Ito, K.
    Shibata, Y.
    Shimizuguchi, T.
    Nihei, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E236 - E236
  • [28] Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer
    Lee, Sang Hoon
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2024, 84 (03): : 103 - 110
  • [29] ASO Author Reflections: Is Neoadjuvant Chemotherapy Associated with Acceptable Short-Term Outcomes for Pancreatic Cancer?
    Kamarajah, Sivesh K.
    Dahdaleh, Fadi
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (04) : 1906 - 1907
  • [30] ASO Author Reflections: What is the Optimal Method for Predicting a Response to Neoadjuvant FOLFIRINOX Chemotherapy for Pancreatic Cancer?
    Yun, Won-Gun
    Jang, Jin-Young
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (03) : 1488 - 1489
12345